Covid 19: 5 vaccine in phase III trials now

26 Sep 2020 07:39 PM

The spread of coronvirus cases in India and across the globe is not under control. In India, the cases have almost reached 60 lakhs and India could overtake US anytime soon to become worst hit nation.



Looks as if only a vaccine is what is likley to give confidence to India to come out and live a normal life.


There are five potential vaccines undergoing phase three of human trials across the globe giving a ray of hope that we might get a vaccine soon.


Vaccine developers Moderna, Pfizer, Oxford University and Astra Zeneca, Johnson & Johnson, Novavax are at present undergoing phase III of human trials. Out of which, Oxford University, Johnson Jhonson and Novavax will give their vaccine's to India.


Our own indigenous coronavirus vaccine Covaxin will enter phase III of human clinical trials.




Moderna

*Covid vaccine based on genetic material or mRNA instructs human cells to make SARS-CoV2 antigen, eliciting an immune response.


Moderna


*The company initiates phase-3 or late-stage, clinical trials on July 27 and being tested on 30,000 participants.


Moderna


*Moderna’s first interim analysis will come after 53 trial subjects become infected.


Pfizer-BioNTech

*Pfizer and German firm BioNTech vaccine instructs human cells to make SARS-CoV2 antigen, eliciting an immune response.

*It could create history by being the first vaccine to get US approval.


Pfizer-BioNTech


*It initiated phase-II/III clinical trials on July 27 and it is being tested on 30,000 participants in the US and countries like Argentina Brazil, and Germany.


Pfizer-BioNTech

*Pfizer's first interim analysis will come after 32 coronavirus trial subjects become infected. By the end of October, it will come to know whether the vaccine works.


AstraZeneca-University of Oxford


*The British-Swedish pharma major AstraZeneca & the University of Oxford vaccine based on a chimpanzee adenovirus.


AstraZeneca-University of Oxford

*It has been modified to carry coronavirus genes and deliver them into human cells.

*It is undergoing phase III clinical trials on more than 17,000 volunteers.


AstraZeneca-University of Oxford

*Serum Institute of India is testing it on 1,700 participants in India

*AstraZeneca said its first interim analysis will come after 75 coronavirus trial subjects become infected.


Johnson & Johnson

*Johnson & Johnson vaccine based on adenovirus vector Ad26. The company has used the same viral platform to develop vaccines for Ebola and other viruses such as Zika, RSV and HIV.

*Johnson & Johnson became the fourth company to initiate a global phase-3 trial.


Johnson & Johnson


*It took just three months for the company to move from phase 1/2 to a late-stage trial.

*The company plans to enrol up to 60,000 volunteers across three continents and will study the safety and efficacy of a single vaccine dose.


Johnson & Johnson

*If proven to be safe and effective, the first batch of the vaccine should be available for emergency use in early 2021.

*The vaccine would be distributed in India through J&J partner Biological E.


Novavax

*Novavax vaccine is a protein sub-unit vaccine that uses part of the virus and combines with adjuvant, or booster, to deliver it as a vaccine.


Novavax

*Novavax initiated phase-3 trial on September 24 in the UK and is expected to enroll up to 10,000 individuals between 18-84 years of age over the next four to six weeks.


Novavax

*The company expects to roll out the vaccine by mid-2021.

*Serum Institute of India to produce as many as 2 billion doses a year.



Sputnik

*Sputnik V developed by Moscow’s Gamaleya Institute, the Russian Defence Ministry and the sovereign Russian Direct Investment Fund.

Sputnik

*It became the first vaccine to be cleared for public use even before being tested for safety and efficacy.

*The vaccine is based on a modified human adenovirus as vector, which carries the protein of the SARS-CoV-2 virus.


Sputnik

*Sputnik V Phase 1/2 clinical trials on 76 people triggered a strong immune response. Russia is enrolling 40,000 volunteers as part of phase-3, starting September & will take six months to complete.

*Vaccine is available for public in Russia but the vaccine may not be available in other countries.

*Vaccine would be distributed in India through Dr Reddy’s.


Covaxin

*The indigenous vaccine developed by Bharat Biotech in collaboration with ICMR & National Institute of Virology. It had transferred the SARS-CoV-2 virus strain.


Covaxin


*The vaccine has been found to have elicited immune response in monkeys.

*It plans to launch Covaxin Phase -3 trials in October on about 30,000 volunteers in India and other countries.

*The vaccine is unlikley to be launched until the first half of 2021.


Zydus Cadila

*Another indigenous vaccine consists of genetic material of SARS-CoV-2 proteins that instructs human *cells to make SARS-CoV2 antigen, eliciting an immune response.


Zydus Cadila

*The company plans to test its vaccine on about 15,000-20,000 people in Phase-3.

*The launch of the vaccine is expected in the first half of 2021.



Reporter: Sameep Narvekar | Desk: Sameep Narvekar



What do you feel

Click here